Carpal Tunnel Syndrome, Median Neuropathy, Carpal Tunnel
Conditions
Brief summary
This study aims to investigate the role of inflammation in carpal tunnel syndrome (CTS) using a prospective cohort study design. The study will involve a sample of at least 50 individuals with CTS who will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The primary outcome measures include inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity. Data will be analyzed using regression analysis to determine the relationship between inflammation and CTS. The study is expected to provide information on the role of inflammation in CTS and inform the choice of drug and concentration for transdermal drug administration.
Interventions
DIAGNOSTIC_TESTInflammatory markers
Participants in this cohort will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The evaluation will include assessments of inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity.
Sponsors
Ahram Canadian University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Individuals aged 18 years or older * Diagnosis of carpal tunnel syndrome based on clinical symptoms and nerve conduction studies * Willingness and ability to provide informed consent to participate in the study * Willingness and ability to comply with study procedures and follow-up visits
Exclusion criteria
* Presence of other neurological conditions that may affect nerve function in the upper extremities * Use of medications that may affect inflammation or carpal tunnel syndrome severity * History of previous carpal tunnel release surgery on the affected wrist * Inability to comply with study procedures or follow-up visits * Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The relationship between inflammatory markers and symptom severity of carpal tunnel syndrome (CTS). | Changes of inflammatory markers and symptoms severity at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline | interleukin-6, tumor necrosis factor-alpha using blood tests. Symptom severity will be assessed with standardized questionnaire the Boston Carpal Tunnel Questionnaire. |
| The relationship between inflammatory markers and grip strength of patients with CTS. | Changes of inflammatory markers and grip strength at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline | interleukin-6, tumor necrosis factor-alpha using blood tests. functional status by grip strength using a dynamometer. |
| The relationship between inflammatory markers and pinch strength of CTS patients. | Changes of inflammatory markers and pinch strength at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline | interleukin-6, tumor necrosis factor-alpha using blood tests. pinch strength will be measured using a dynamometer |
| The relationship between inflammatory markers and nerve conduction study of patients with CTS | Changes of inflammatory markers and nerve conduction study at baseline, 4 weeks, 8 weeks, and 12 weeks after baseline | interleukin-6, tumor necrosis factor-alpha using blood tests. Nerve conduction study results (motor and sensory distal latency of median nerve and amplitude) will be used to determine CTS severity based on Bland's grading scale. |
Countries
Egypt
Contacts
Primary ContactMohamed M ElMeligie, Ph.d
Outcome results
None listed